2 Mid-Cap Stocks Down 25% to Buy Now
Concerns over rising energy prices, surging inflation, the Ukraine and Russia war, and rising COVID-19 cases in China have made the stock market extremely volatile. Also, the Fed’s decision to hike the interest rates further in May by 50 basis points to attack multi-decade high inflation has also caused the benchmark indexes to tumble recently.
The S&P is down 5.2% so far in April and is very close to posting its worst monthly performance since March 2020, i.e., during the COVID-19-led collapse in equities.
Given this backdrop, we think investing in fundamentally sound mid-cap stocks Bruker Corporation (BRKR) and PVH Corp. (PVH) could significantly help investors hedge the current market volatility. These stocks are down more than 25% in price year-to-date, offering attractive entry points.
Bruker Corporation (BRKR)
With a market capitalization of $8.81 billion, BRKR in Billerica, Mass., develops, manufactures, and distributes scientific instruments and analytical and diagnostic solutions in the United States and internationally. Bruker Scientific Instruments (BSI) Life Science; BSI NANO; and Bruker Energy & Supercon Technologies are the company’s three operational segments.
At the 32nd European Congress of Clinical Microbiology & Infectious Diseases, BRKR announced further improvements in its market-leading MALDI Biotyper (MBT) platform and launched new multiplex PCR infectious disease assays that are based on its proprietary LiquidArray technology. BRKR further expands its mycobacteria portfolio with the FluoroType Mycobacteria PCR assay, launched on the high-precision FluoroCycler XT thermocycler.
During the fourth quarter, ending Dec. 31, 2021, BRKR’s revenue increased 8.9% year-over-year to $683.5 million. Its non-GAAP operating income grew 1.9% from its year-ago value to $143.8 million, while its net income attributable to BRKR amounted to $90.2 million, up 1.5% from its prior-year quarter. The company’s non-GAAP EPS rose 1.7% year-over-year to $0.59.
Analysts expect BRKR’s revenue to increase 3.2% year-over-year to $572.50 million for the first quarter, ended March 31, 2022. The $0.39 consensus EPS estimate represents a 2.6% improvement year-over-year during the second quarter, ending June 30, 2022. In addition, the company has an impressive earnings history; it surpassed the consensus EPS estimate in three of the trailing four quarters. The stock has plunged 30% in price year-to-date.
BRKR’s POWR Ratings reflect this promising outlook. The company has an overall rating of B, which translates to Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 distinct factors, each with its own weighting.
BRBR is also rated a B grade for Value and Quality. Within the Medical – Diagnostics/Research industry, it is ranked #4 of 49 stocks.
To see additional POWR Ratings for Growth, Stability, Sentiment, and Momentum for BRKR, click here.
Continue reading at STOCKNEWS.com